News

ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes

Full results from REGEN-007 are being held and will be submitted to the American Society of Nephrology 2025 Kidney Week…

6 months ago

Microbix & Bulgaria’s NCIPD Execute Supply Agreement

Microbix to Develop New Products using NCIPD Organism CollectionMISSISSAUGA, Ontario and SOFIA, Bulgaria, July 08, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc.…

6 months ago

CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025

BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for…

6 months ago

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)

- NDA assigned a Target Action Date of February 25, 2026 -- Product has patent protection through 2044 - DEER…

6 months ago

WeightWatchers Completes Financial Reorganization, Strengthens Leadership, and Expands Program Innovation to Support Women Through Menopause

With renewed financial strength, WeightWatchers accelerates its transformation with the appointment of key executives including Dr. Kim Boyd as Chief…

6 months ago

Comphya Closes Oversubscribed CHF 7.5 Million Series A Round to Advance U.S. and Australian Clinical Programs Following Strong Pilot Data

- IDE approval obtained; U.S. pilot study clinical site launched at Johns Hopkins- Series B round in planning to support…

6 months ago

UAE Approves BioAro’s Longevity+ Supplement, Signaling Major Market Potential in Global Preventive Health

With a patent-pending formula and international expansion underway, BioAro positions itself as a front-runner in the multi-billion-dollar longevity and wellness…

6 months ago

AB Science announces the successful completion of a EUR 1.925 million private placement

PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 1.925 MILLION PRIVATE PLACEMENT Paris, July 8, 2025, 8am…

6 months ago

Novartis receives approval for first malaria medicine for newborn babies and young infants

Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries…

6 months ago

Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 08, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a…

6 months ago